License agreement provides StemSight access to CRISPR/Cas9 technology to be applied in development of cell therapies for corneal blindness.
‘They see a cash cow’: Corporations could consume $50 billion of opioid settlements
The marketing pitches are bold and arriving fast: Invest opioid settlement dollars in a lasso-like device to help police detain people without Tasers or pepper
December 18, 2023